




Uscom


Q4 Briefing 2020

ASX: UCM



May 1ST 2020

Prof. Rob Phillips
PhD(Med), MPhil(Med), FASE, DMU(Cardiol)
Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia
Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia



“Uscom has a dedicated focus on the development and marketing of innovative non-invasive cardiovascular and pulmonary medical devices


Current record revenue growth is from the USCOM 1A, and we have a constellation of new products in development and approaching regulatory approval worldwide to generate future incremental growth through our expanding global distribution channels

Uscom devices are playing a unique and life saving role in the current global health crisis with new products poised to contribute significantly to clinical recovery strategies”

Prof. Rob Phillips



2020: Q3 RESULTS



ASX:UCM

- Profit up \$0.96M
- Cash flow up \$1.39M
- Cash receipts up 135%
- Cash on hand up 63%
- Debt free





OPERATIONS



1. Q3 - Profitable, cash flow positive, record cash receipts, cash on hand, debt free

2. Uscom China continues growth with strong Q4 orders

3. Europe and US COVID -19 sales activity increasing

4. Lung recovery monitoring for all COVID patients

5. New products for market in second half

Uscom – The Measure of Life





THE USCOM MISSION

Ambitious and growth driven



Who We Are

Uscom are the experts in circulation delivering innovative, practice changing non-invasive cardiovascular and pulmonary monitoring devices to global markets.



Our Vision

To improve clinical care in cardiovascular and pulmonary medicine and address the challenges of global disease.



Our Drive

A commercial ambition to become a leader in global healthcare, and establish a profitable and enduring growth culture.

Uscom – The Measure of Life





PRODUCT SUITES

Uscom cardiovascular and pulmonary devices address diseases which account for >75% of global mortality



SpiroSonic
 COVID-19, ASTHMA, COPD, OLD
 Uscom digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi-path ultrasound technology.



USCOM 1A
 SEPSIS (COVID-19), HEART FAILURE, FLUID
 A non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler ultrasound.




BP+
 HYPERTENSION, VASCULAR DIS.
 Central and brachial blood pressure and pulse pressure waveforms, information only previously available using invasive cardiac catheterization using suprasystolic oscillometry.

Uscom – The Measure of Life





GROWING GLOBAL



Multiple products, currencies and markets





PEOPLE



Rob Phillips



Nick Schicht



Teresa Guo



Lucy Lu



Lebron Wei



Denise Pater



Rik Denicke



George Ferenczi



Nancy Wang



Scarlett Zhang



Curt Grosse



Daniel Kenig



Richard Scott



Zsafia Kertesz



Crystal Lin



George Tang




Susanna Sun



Andrea Marosan



Antonio Ferrario



Szabo Gergo



Catherine Gao



Leo Luo



Helen Zhang



Hagay Gilad

37 employees
4 continents




COVID-19

Viral lung infection ultimately may infect ~30M patients worldwide and kill ~0.5M

This has prompted a transformational response from health systems worldwide with a commitment to massive spending over the next two years

Precision, non-invasive medical devices will be an important part of the re-equipping of public health systems worldwide





COVID-19 and USCOM 1A

SEVERE COVID-19 TREATMENT

(in the absence of a vaccine)

1. RESPIRATORY SUPPORT – VENTILATORS

Simple and common

2. CARDIOVASCULAR SUPPORT

– USCOM 1A

Less common but more critical





COVID-19 and USCOM 1A



COVID-19 patients on ventilators ~90% mortality
Ventilators not the solution

COVID-19 patients with cardiovascular damage have
10x mortality – Heart and vessels critical

***“VENTILATORS ARE EVERYWHERE, BUT USCOM IS NOW
BEING RECOGNISED IN INSTITUTIONS OF EXCELLENCE”***

Uscom – The Measure of Life



Uscom

COVID-19 and USCOM 1A

USCOM 1A China Government Recommendations

Recommended by Chinese National Health and Medical Commission of the People's Republic of China for Treatment of Severe Coronavirus in Adults and Children



The China National Health and Medical Commission of the People's Republic of China

“Protocol for Diagnosis and Treatment of Severe and Critical Cases Infected with the New Coronavirus Pneumonia (2nd Edition for Trial Implementation) on the 14th February, which definitively describes the recommended monitoring technology and states under the treatment section 3.

“2) Simple and easy to maintain and manage haemodynamic monitoring techniques should be selected. We do not recommend the use of complex invasive haemodynamic monitoring at the bedside. Ultrasound Doppler is a noninvasive and convenient monitoring method, and should be actively adopted if possible.”

USCOM 1A is the only globally available Doppler Haemodynamic Monitor and is specialised for management of sepsis

Chinese National Health and Medical Commission Guidelines (v1-6) – January 26th
Chinese National Health and Medical Commission Guidelines (Edition 2) – February 14th
Wuhan and Hubei academies Pediatric Coronavirus Guidelines – February 10th
SCCM International Sepsis Guidelines for Children – 21st February

Uscom – The Measure of Life





SEPSIS IN CHILDREN (COVID-19)



USCOM 1A SCCM Pediatric Sepsis Guidelines



Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children

Scott L. Weiss, MD, MSCE, FCCM (Co-Vice Chair); Mark J. Peters, MD, PhD (Co-Vice Chair); Waleed Alhazzani, MD, MSc, FRCPC (Methodology Chair); Michael S. D. Agus, MD, FCCM, FAAP; Heidi R. Flori, MD, FAAP³; David P. Inwald, MB, BChir, FRCPC, FFICM, PhD³; Simon Nadel, MBBS, MRCP, FRCP³; Luregn J. Schlapbach, FCICM, FMH-ICU, FMH-Paed, FMH-Neonatology²; Robert C. Tasker, MB BS, MA, AM, MD, FRCPC, FRCP³; Andrew C. Argent, MB BCh, MMed, MD (Paediatrics)³; Joe Brierley, MD, MA³; Joseph Carcillo, MD³; Enitan D. Carrol, MB ChB, MD, FRCPC, DTMH¹; Christopher L. Carroll, MD, MS, FCCM, FAAP¹²; Ira M. Cheifetz, MD, FCCM¹³; Karen Choong, MB, BCh, FRCP(C) (methodologist)³; Jeffrey J. Cies, PharmD, MPH, BCPS-AQ ID, BCPPS, FCCP, FCCM, FPPAG¹⁴; Andrea T. Cruz, MD, MPH, FAAP¹⁵; Daniele De Luca, MD, PhD^{16,17}; Akash Deep, MB BS, MD, FRCPC¹⁸; Saul N. Faust, MA, MB BS, FRCPC, PhD, FHEA¹⁹; Claudio Flauzino De Oliveira, MD, PhD²⁰; Mark W. Hall, MD, FCCM, FAAP²¹; Paul Ishimine, MD, FACEP, FAAP²²; Etienne Javouhey, MD, PhD²³; Koen F. M. Joosten, MD, PhD²⁴; Poonam Joshi, PhD²⁵; Oliver Karam, MD, PhD²⁶; Martin C. J. Kneyber, MD, PhD, FCCM²⁷; Joris Lemson, MD, PhD²⁸; Graeme MacLaren, MD, MSc, FCCM²⁹; Nilesh M. Mehta, MD³; Morten Hylander Møller, MD, PhD³⁰; Christopher J. L. Newth, MD, ChB, FRCPC, FRACP³¹; Trung C. Nguyen, MD, FAAP¹⁵; Akira Nishisaki, MD, MSCE, FAAP³; Mark E. Nunnally, MD, FCCM (methodologist)³²; Margaret M. Parker, MD, MCCM, FAAP³³; Raina M. Paul, MD, FAAP³⁴; Adrienne G. Randolph, MD, MS, FCCM, FAAP³; Suchitra Ranjiti, MD, FCCM³⁵; Lewis H. Romer, MD³⁶; Halden F. Scott, MD, MSCS, FAAP, FACEP³⁷; Lyvonne N. Tume, BS, MSN, PhD, RN³⁸; Judy T. Verger, RN, PhD, CPNP-AC, FCCM, FAAN³⁹; Eric A. Williams, MD, MS, MMM, FCCM, FAAP¹⁵; Joshua Wolf, MBBS, PhD, FRACP⁴⁰; Hector R. Wong, MD⁴¹; Jerry J. Zimmerman, MD, PhD, FCCM⁴²; Niranjan Kissoon, MB BS, MCCM, FRCP(C), FAAP, FACPE (Co-Chair)⁴³; Pierre Tissieres, MD, DSc (Co-Chair)^{16,44}

International Guidelines from US, UK, Europe, Canada, S America, India, Australia

51 Authors, 25% of authors are USCOM users or advocates


Weiss SL, Alhazzani W, Flori HM et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis Associated organ Dysfunction in Children. Society of Critical Care Medicine, the European Society of Intensive Care Medicine, and the World Federation of Pediatric Intensive and Critical Care Societies. Crit Care 2020;21(2):e52-e106, DOI: 10.1097/PCC.0000000000002198

Uscom – The Measure of Life







COVID-19 THE FUTURE



COVID Pulmonary Fibrosis



~10M COVID-19 infections worldwide

Recovery complicated by pulmonary fibrosis and reduced lung function

The long term effects of COVID-19 on lung function are unknown

Digital ultrasonic spirometry most accurate method of monitoring changes

Clinic, eHealth and home care

Market predicted to double in 12 months
\$2.6B to \$6.5B (MarketandResearch)

For every breath you take



Uscom




COVID-19 RECOVERY - NEW PRODUCT



New Product - SpiroSonicAIR for the acute and chronic recovery phases of COVID-19 with pulmonary fibrosis, asthma and COPD

World leading spirometers

1. Digital multi-path ultrasonic technology
2. High sensitivity (2.5%), durable, simple disinfection
3. Wireless connectivity to App and software
4. Induction charging
5. 5000 unit sales ~\$10M revenue
6. Home care and eHealth




For every breath you take





NEW PRODUCT – VENTILATOR TEST



VentiTest is a multi-path ultrasonic ventilator test device with PC based display and analytics designed for pressure and flow testing and calibration of ventilator outputs.

Uscom is increasing manufacture and marketing of VentiTest
Hospital Departments need 1 VentiTest per 10 ventilators, Estimated 10,000 unit sales = \$25M revenue




High Market Interest

Exploding demand for COVID-19 ventilators worldwide
Around 1M ventilators all require regular calibration

Unique Technology

Based on multi-path digital ultrasound





USCOM FOR ALL PHASES OF COVID-19

“Uscom for the acute, critical and recovery phases of COVID-19”

COVID-19 is a respiratory virus which is often impairs lung and can be complicated by pneumonia, sepsis and pulmonary fibrosis.

1. Pulmonary consolidation – SpiroSonicAIR

2. Sepsis and cardiovascular failure – USCOM 1A monitoring

3. COVID recovery (pulmonary fibrosis) – SpiroSonicAIR eHealth

4. Ventilator calibration – Uscom VENTITEST calibration

Uscom – The Measure of Life





INNOVATION

Uscom technology provides the highest quality personal spirometers allowing home lung function testing at research standards.



Uscom Digital Spirometry Ultrasonic Flow Technology



“FOR MEDICAL TECHNOLOGY COMPANIES
INNOVATION DETERMINES FUTURE REVENUE

USCOM CONTINUES TO DEVELOP NEW
DEVICES AND IMPROVES CURRENT
TECHNOLOGIES”





A&D PARTNERSHIP FOR BP+

Hypertension is common and dangerous

40% of all people over 25yrs have hypertension

Hypertension complicated by Heart Attack, Stroke, and kidney failure

Hypertension is responsible for 7.5M US deaths

Management is widely ineffective

\$130B spent on US hypertension yet only 20% of hyperensives have controlled BP

This may in part be due to poor BP technologies

BP+ developed to set new standards for hypertension

Uscom have co-developed a new module for precision monitoring of BP with Japanese industrial measurement leaders A&D for use in BP+



The new A&D module is now included in all BP+ devices

Uscom – The Measure of Life





STRATEGY



- 1. Focus on China sales and distribution expansion**
- 2. Grow Europe and US sales activities around COVID-19**
- 3. New products for global markets – BP+, SpiroSonicAIR and VENTITEST**
- 4. Develop eHealth features for COVID-19 recovery monitoring**
- 5. Grow global manufacturing capabilities to meet demand**
- 6. Global digital marketing strategies**
- 7. Develop SE Asia HQ in Singapore**
- 8. Drive global regulatory approvals – new revenue streams for second half 2020**

Global growth strategy is focused on more products and more extensive distribution






UCM - TIGHTLY HELD



Quality growth stock
Invested management
Undergoing revaluation

~150M FPO UCM shares on issue
~35±10c (Current price 24c)
~\$35M Cap Value
Top 20 own 68%
CEO and NED own ~20% each
China Director and Distributor owns ~1.5% each

Shareholding



UCM is tightly held by experienced investors





SUMMARY

SUMMARY

- 1. Profitable, cash flow positive, record cash receipts, cash on hand and debt free**
- 2. Continuing strong growth forecasts for Uscom China**
- 3. Europe and US distribution showing sales pipeline growth (COVID-19)**
- 4. COVID-19 recovery monitoring likely to impact device demand in US**
- 5. Sustained organic growth; 6yr - 358% total**
- 6. Incremental growth trend - Two corporate acquisitions**
- 7. Multiple products, Multiple jurisdictions, Multiple currencies**

Uscom – The Measure of Life





CONCLUSION



“Uscom has an established growth history, with rapidly transforming fundamentals and a clear strategy focused on more products and more distribution

Uscom is part of the emergency global response to the Coronavirus pandemic, and is now developing strategies to manage COVID-19 recovery patients

Uscom has innovative technologies that deliver global health solutions and save lives in an unpredictable world”

Prof Rob Phillips CEO

Uscom – The Measure of Life





Uscom

Q4 Briefing 2020

ASX: UCM



May 1ST 2020

Prof. Rob Phillips

PhD(Med), MPhil(Med), FASE, DMU(Cardiol)
Chairman, CEO, Chief Scientist, Uscom Limited, Sydney,
Australia
Critical Care Research Group, School of Medicine, The
University of Queensland, Brisbane, Australia



Please support

Corporate Social Responsibility



australian
wildlife
conservancy

www.australianwildlife.org



Uscom



Uscom - improving the quality of life for us all